4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Sarcoidosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 113 ongoing clinical trials involving Sarcoidosis
Of the 113 trials,46 trials are in Phase II/III
Furthermore, 35 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Sarcoidosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Sarcoidosis, an immunology disorder. The largest number of ongoing clinical trials for Sarcoidosis is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Sarcoidosis-related drug trials.

Sarcoidosis related clinical trial sponsor

Erasmus MC, University of Cincinnati, Postgraduate Institute of Medical Education and Research, University of Texas Southwestern Medical Center, Western Sydney Local Health District (Australia), and Ottawa Heart Institute Research Corp are among other notable clinical trial sponsors involved in Sarcoidosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Sarcoidosis

Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar), Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone), and Prednisone (Rayos, Lodotra, Nocasio) are among the key marketed drugs involving Sarcoidosis.

Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) is a purified preparation of the adrenocorticotropic hormone (ACTH) obtained from porcine pituitary. It functions via Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Agonist; Melanocortin Receptor 3 (MC3R) Agonist; Melanocortin Receptor 4 (MC4R) Agonist; Melanocortin Receptor 5 (MC 2 or MC5R) Agonist; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Agonist mechanism of action.  It is formulated as injection gel for intramuscular and subcutaneous route of administration and powder for solution for intravenous, intramuscular and subcutaneous routes of administration. Corticotropin, Repository Corticotropin is marketed for the treatment of Sarcoidosis and several other indications including Stevens-Johnson Syndrome (SJS), Proteinuria, Juvenile Rheumatoid Arthritis, Serum Sickness, Polymyositis, Keratitis, Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, Infantile Spasm (West Syndrome), Dermatomyositis, Rheumatoid Arthritis, and Systemic Lupus Erythematosus. Corticotropin, Repository Corticotropin was first approved in 1950 and is marketed in the US, and New Zealand by Mallinckrodt LLC, and Sanofi.

Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone) is a glucocorticoid, anti-inflammatory agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as tablets for oral administration, lyophilized powder for solution, suspension and solution for intravenous, intramuscular, intraarticular, intralesional, intrasynovial route of administration. Methylprednisolone is marketed for the treatment of Sarcoidosis and several other indications including Arthritis, Osteoarthritis, Asthma, Allergic Rhinitis, Lupus Nephritis, Hypoglycemia, Alopecia, Seborrhea, Liver Cirrhosis, Proteinuria, Myasthenia Gravis, Sarcoidosis, Fever, Uveitis, Hematopoietic Stem Cell Transplantation, Pneumonia, Juvenile Rheumatoid Arthritis, Hemorrhagic Shock, and Vasculitis. Methylprednisolone was first approved in 1957 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Pfizer Inc, Pharmacia LLC, and Greenstone LLC.